The U.S. Patent and Trademark Office’s (USPTO) new proposal would change the criteria for challenging patents. Concerned that the proposed change would make it easier for branded drug companies to exclude generic drugs from the market and cause an increase in already unaffordable prescription drug prices, Open Markets Institute submitted a letter to the USPTO.
The Open Markets Institute submitted a comment to the Patent and Trademark Office regarding Docket No. PTO-P-2018-0036: Changes to the Claim Construction Standard for Interpreting Claims in Trial Proceedings Before the Patent Trial and Appeal Board.
Read the full comment here.